GenrAb, Inc. is harnessing the power of adaptive human immunity to discover neuroprotective and neurotherapeutic human antibodies. Guided by proprietary immunogenetic models, the Company interrogates the cerebrospinal fluid in patients with active neurological disease to harvest novel human disease associated antibodies. Antibodies such as TGM-010, are selected based on their antineuronal capabilities and potential for managing neuronal stress to preserve cell function and survival. Using this unique approach, GenrAb is building a pipeline of patented therapeutic antibodies that can durably reduce disability in patients suffering from neurodegenerative disease, democratizing the availability of even rare antibodies found only in certain patients with neurological disease.